Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib combined with EGFR-TKI after acquired EGFR-TKI resistance in NSCLC
ChiCTR-OIN-17012051Phase 4Recruiting
- Sponsor
- Shanxi Cancer Hospital
- Start
- Mar 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib, erlotinib, gefitinib and icotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanxi Cancer Hospital. Primary endpoint: Progression-free survival. Started Mar 2017; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-OIN-17012051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIN-17012051.